Overview of Zerodol-TH

Zerodol-TH is a prescription medication designed as a Fixed-Dose Combination to address both inflammation and painful muscle spasms.

Property	Description
Active ingredients	Aceclofenac, Thiocolchicoside
Form	Oral Tablet
Pharmacological class	NSAID and Skeletal Muscle Relaxant
Common purpose	Relief of pain and muscle stiffness
Origin	Synthetic derivative (Aceclofenac) and semi-synthetic derivative (Thiocolchicoside)

What is Zerodol-TH and How is it Classified?

Zerodol-TH is classified as a Fixed-Dose Combination (FDC) medicine, meaning it contains two active substances in a single oral tablet. The drug combines an anti-inflammatory agent with a muscle relaxant, classifying it as a combination of a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a Skeletal Muscle Relaxant. The muscle relaxant component, Thiocolchicoside, is a semi-synthetic derivative of the natural compound colchicine.

This specific Aceclofenac and Thiocolchicoside formulation is widely clinically recognized for its efficacy in relieving musculoskeletal discomfort where patients experience both pain and stiffness.

What is the Composition of Zerodol-TH?

The active ingredients are Aceclofenac (the NSAID) and Thiocolchicoside (the muscle relaxant). Aceclofenac works to reduce inflammation, swelling, and pain by inhibiting key chemical messengers. Thiocolchicoside acts centrally to help relieve painful muscle contractions, spasms, and tension.

Pharmacological data supports the use of this combination for associated muscle spasm, confirming the rationale for combining these two classes of medicine.

What is the General Purpose of Zerodol-TH?

The primary purpose is to provide integrated relief from musculoskeletal discomfort characterized by both pain and involuntary muscle tension. By using a dual-action approach, the medication aims to achieve more comprehensive relief by addressing the root inflammation while simultaneously easing the painful rigidity caused by the muscle spasms.

What side effects are possible with Zerodol-TH?

Possible Side Effects and Safety Information

Zerodol-TH, a combination product containing a Non-Steroidal Anti-Inflammatory Drug (NSAID) and a muscle relaxant, carries risks associated with both classes of agents. All reported adverse reactions are based on official regulatory documentation and established frequency classifications.

Adverse Reactions

Common adverse effects frequently involve the Gastrointestinal System and Nervous System. These include nausea, vomiting, heartburn, abdominal pain, diarrhea, loss of appetite, dizziness, drowsiness, and elevated liver enzymes in the blood.

Serious and Clinically Significant adverse reactions, though less common, require immediate attention. These primarily include gastrointestinal bleeding or ulceration, severe allergic reactions (e.g., anaphylaxis, serious skin reactions), liver toxicity, and kidney damage, especially with prolonged use. Cardiovascular risks, such as increased blood pressure and heart failure, are also documented.

System-Organ Class	Common Adverse Reactions
Gastrointestinal	Nausea, Vomiting, Abdominal Pain, Diarrhea
Nervous System	Dizziness, Drowsiness
Hepato-biliary	Increased Liver Enzymes

Safety Considerations and Restrictions

Contraindications are absolute restrictions for use. This medicine is formally contraindicated in patients with known hypersensitivity to its components or other NSAIDs, active or history of recurrent stomach ulcer/bleeding, severe hepatic or renal impairment, severe heart failure, and during the entire period of pregnancy and breastfeeding.

Population-Specific Warnings: The use of this medicine is generally not recommended in children under 18 years of age. Given the risks of genotoxicity found in preclinical studies for the muscle relaxant component, use in women of childbearing potential is strictly contraindicated unless effective contraception is used. Caution is required in older adults and patients with pre-existing mild-to-moderate liver or kidney disease, or controlled high blood pressure.

Overdose and Emergency Response

The official documentation for an overdose of Zerodol-TH (Aceclofenac and Thiocolchicoside) is primarily structured around the recognized risks associated with the NSAID component and the required immediate actions.

Documented Manifestations and Severe Outcomes

An overdose may present with symptoms such as nausea, vomiting, epigastric pain, drowsiness, and dizziness. In cases of severe exposure, the official labeling documents the potential for life-threatening outcomes, including acute renal failure, Gastrointestinal bleeding, liver damage, convulsions (seizures), respiratory depression, and coma. Close monitoring of renal and hepatic function is required in this scenario.

Emergency Action Required

In the event of an overdose or suspicion of one, contact a poison control center immediately. Urgent medical attention must be sought for any sign of severe complication, particularly if symptoms escalate or if an anaphylactic reaction occurs. The labeling states that overdose management requires close medical supervision and symptomatic and supportive treatment, as no specific antidote is known for the active ingredients.

Official Procedural Notes

To reduce drug absorption, activated charcoal and gastric lavage should be considered by a healthcare professional, especially within the first hour after ingestion of a potentially toxic amount. The use of procedures like forced diuresis or hemodialysis is generally not considered beneficial due to the high protein binding of the Aceclofenac component. Specific guidance on pediatric dosage for activated charcoal is documented in regulatory materials.

Therapeutic Uses of Zerodol-TH

Zerodol-TH is commonly used to help manage symptomatic discomfort where symptoms related to physical discomfort and muscular tension occur together. This dual-action therapy is utilized for various painful muscular disorders.

The medication is generally used across conditions presenting with acute episodes and heightened symptoms, particularly low back pain (lumbago), neck stiffness (cervical spondylosis or torticollis), and flare-ups associated with degenerative vertebral and joint disorders such as osteoarthritis. It is also often used during phases when symptoms become more noticeable following acute events like sprains and strains, or as part of post-operative recovery.

The core use is providing supportive relief that provides support that helps ease the symptom load of both pain and involuntary muscular contractions. As patients often seek relief when symptoms create noticeable functional strain, the medication assists with maintaining functional stability during difficult episodes.

“The medication is relevant for easing the combination of pain and functional stiffness that may disrupt daily stability.”

Quick Fact: Relief for Pain and Spasm
Therapeutic Target: Symptoms related to physical discomfort, inflammation, and muscular tightness.
Typical Use Context: Acute or episodic symptoms from joint/spinal disorders and soft-tissue injury.
Patient Benefit: Supports management of symptomatic strain and assists with maintaining functional comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Zerodol-TH?

The eligibility for Zerodol-TH is determined by official regulatory guidelines, which are defined by contraindications for both active components, Aceclofenac (NSAID) and Thiocolchicoside (Muscle Relaxant).

Contraindicated Populations

Zerodol-TH is strictly contraindicated for several populations, including:

Children and Adolescents under 16 years of age.
Pregnant women and women who are breastfeeding.
Women of childbearing potential who are not using effective contraception.
Patients with severe heart failure, severe liver failure, or severe kidney failure.
Individuals with a history of active or recurrent gastrointestinal bleeding or peptic ulcers.
Those with known hypersensitivity to NSAIDs, which may trigger asthma, rhinitis, or urticaria.

Restricted and Conditional Use

Use is subject to caution and close medical supervision for specific populations and conditions:

Elderly patients, due to an increased risk of adverse reactions.
Patients with mild to moderate hepatic or renal impairment.
Individuals with a history of epilepsy or an increased risk of epileptic seizures.
Those with established cardiovascular disease or uncontrolled hypertension.

Only adults and adolescents 16 years or older who meet the official criteria and do not present any absolute contraindications are eligible for use.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Zerodol-TH contains Aceclofenac (an NSAID) and Thiocolchicoside, and its interaction profile is primarily defined by the risks associated with the Aceclofenac component.

Key Interacting Medicinal Products and Risk

Product Category	Interaction Implication
Other NSAIDs/Aspirin	Increased risk of gastrointestinal bleeding and adverse events; concurrent use is generally avoided.
Anticoagulants (e.g., Warfarin)	Significantly enhanced risk of haemorrhage due to additive anti-platelet and GI effects.
Diuretics / Antihypertensives	Reduced blood pressure control and increased risk of nephrotoxicity (kidney damage).
Lithium / Digoxin / Methotrexate	Increased plasma concentrations of these drugs, raising the potential for toxicity.
Mifepristone	Use must be avoided for a specified period (e.g., 8–12 days) after Mifepristone administration as it can reduce its efficacy.
CNS Depressants	Potential for additive effects, increasing the risk of drowsiness and central nervous system depression (Thiocolchicoside component).

Procedural and Condition-Specific Notes

The interaction profile requires caution in elderly patients and those with pre-existing renal or hepatic impairment, particularly when using nephrotoxic co-medications like Cyclosporine. Alcohol should be avoided as it may enhance the risk of gastrointestinal bleeding and CNS side effects.

Mechanism of Action

The effect of Zerodol-TH is achieved through the dual influence of its components, each operating on a separate, primary physiological pathway: peripheral enzyme inhibition and central nervous system modulation. This dual-site mechanism addresses both the peripheral inflammatory signaling cascade and the resulting state of motor neuron hypertonia.

Mechanism 1: Selective Inhibition of Peripheral Inflammatory Mediators

The Aceclofenac component primarily acts via the inhibition of the Cyclooxygenase-2 (COX-2) enzyme at the site of tissue injury. This molecular interaction suppresses the synthesis of prostaglandins, which dampens the chemical signaling cascade. The resulting physiological effect is a dampening of peripheral nociceptor sensitization and a limitation of vasodilation/capillary permeability.

Mechanism 2: Central Modulation of Muscle Tone and Reflexes

The Thiocolchicoside component exerts a central mechanism within the spinal cord and brainstem, modulating the activity of key inhibitory neurotransmitter systems, namely the GABAA and Glycine receptors. This interaction alters the balance of signals controlling motor neurons, which helps stabilize the spinal reflex arc. The physiological consequence is a decrease in motor neuron hypertonia.

Dosage and Administration Information

How to Use Zerodol-TH: Administration Guidelines

This section describes the instructions for the use of the fixed-dose combination of Aceclofenac (100 mg) and Thiocolchicoside (4 mg or 8 mg), as standardized for this formulation.

Administration Scope

Aspect	General Administration Details
Route of Administration	The medication is for oral administration only, in the form of a film-coated tablet.
Standard Dosing Schedule	The standard regimen involves taking one tablet twice daily (b.i.d.). The maximum recommended daily intake for the Aceclofenac component is 200 mg, delivered in two 100 mg doses.
Timing in Relation to Meals	The tablet must be taken with or immediately after food to aid in gastrointestinal tolerance.
Special Procedural Condition	The tablet must be swallowed whole with water and must not be crushed, broken, or chewed.
Duration Constraint	Treatment with this combination is strictly designated for short-term use only, limited to a maximum of seven consecutive days. This restriction is based on established protocols for the Thiocolchicoside component.

Population-Specific Use Rules

Prescribing information indicates that the medication is not recommended for children or adolescents under 18 years of age. For older adults, the general principle requires using the lowest effective dose for the shortest possible duration to mitigate potential risks. For patients with hepatic impairment, a reduced initial daily dose for the Aceclofenac component may be required, consistent with monotherapy guidance.

Connection to the Overall Use Protocol

This collection of instructions defines a precise, time-constrained protocol for the medication. The requirement for oral, twice-daily administration with food, combined with the limit of seven consecutive days, establishes the specific, short-course framework for the use of this fixed-dose combination.

Recent Clinical Evidence

The evidence landscape for the Aceclofenac-Thiocolchicoside fixed-dose combination (FDC) consists primarily of clinical trials and systematic reviews that research monitored in conditions linked to musculoskeletal pain and spasm. Research has explored outcomes related to physical discomfort and functional ability, particularly during episodes of heightened symptoms. The evidence is generally derived from structured studies and trials that monitor responses over defined time intervals.

Evidence for use in Acute Low Back Pain (LBP) with Muscle Spasm

Research has been applied in studies examining patient-reported experiences for conditions such as low back pain associated with muscle tension. The evidence base includes multiple Randomized Controlled Trials (RCTs) that were studied for their comparison of the FDC against NSAID monotherapy or a placebo. These short-term RCTs included adults experiencing acute episodes of non-specific low back discomfort. Studies report how symptoms evolved in the observed populations by measuring changes in pain intensity using standard scales and functional metrics. Research highlights changes measured during the study period, with some trials describing patterns in the measured outcomes when the FDC was compared to the NSAID component alone.

Evidence for use in Acute Neck Stiffness and Pain

The combination was studied for its use in conditions associated with acute or disruptive episodes, particularly painful neck stiffness (cervical spondylosis or acute nuchal pain). Studies explored how the combination was observed in adult populations presenting with acute restriction of movement. Findings describe patterns observed in these short-term studies, where changes in pain scores and range of motion were monitored during short courses of treatment.

Comparing the Combination against Single-Drug Therapy

A key focus of the research was comparing the combined medicine against its single components. These comparative studies were conducted during periods of increased symptom activity to understand how short-term outcome axes related to the use of the FDC compared to the NSAID alone. The findings generally help contextualize the outcomes when the two-drug combination was observed in comparison to Aceclofenac monotherapy. Comparative evidence is lacking for many other therapeutic combinations, meaning subgroup findings are uncertain outside of the direct comparisons studied.

Duration of Evidence and Research Gaps

The majority of clinical evidence available for this FDC relates to very short-term use, focusing on defined time intervals. Because the available follow-up durations were limited, the long-term effects are not fully established, and there is limited information for long-term outcomes, such as sustained functional stability or recurrence rates. Data for specific special populations, such as pediatric patients or older adults with complex comorbidities, remain insufficient. Research highlights that evidence quality varies across studies due to methodological differences and that the precise clinical relevance of the muscle relaxant component’s measured effect on pain is an area of uncertainty.

Frequently Asked Questions (FAQ)

Common questions about Zerodol-TH (FAQ)

Q: What is the main difference between Zerodol-TH and a regular painkiller?

Zerodol-TH is classified as a fixed-dose combination medicine. It contains not only a pain reliever (Aceclofenac, an NSAID) but also a muscle relaxant (Thiocolchicoside).

This dual composition allows it to address both pain/inflammation and painful involuntary muscle spasms simultaneously, unlike many single-ingredient painkillers.

Q: Is Zerodol-TH effective for pain from old injuries, or only for new spasms?

Official regulatory indications state that this medicine is strictly for the short-term relief of acute, painful muscle contractures.

The available research and regulatory focus are primarily on short-course treatment for acute episodes of pain and stiffness.

Q: Why can Zerodol-TH cause dizziness or drowsiness?

The muscle relaxant component, Thiocolchicoside, is known to act centrally on the body’s nervous system, specifically in the spinal cord and brain.

Dizziness and drowsiness are common effects associated with this central nervous system action, and they are listed as frequent adverse reactions in official safety documents.

Q: Can Zerodol-TH affect the liver over time?

Official product information documents the possibility of liver-related effects. Common reactions include elevated liver enzymes, and rare but serious reactions like liver toxicity or severe liver failure have also been documented.

Because of these risks, regulatory guidelines restrict the duration of treatment to short-term use.

Q: Are there any warning signs for a serious allergic reaction to Zerodol-TH?

Severe allergic reactions, such as anaphylaxis (a serious whole-body reaction) and severe skin reactions, are possible but rare.

Symptoms that have been documented to require immediate medical attention include sudden severe swelling, difficulty breathing, or a widespread rash. The medicine is strictly contraindicated if a known hypersensitivity to its components or other NSAIDs exists.

Q: Why does the medicine information mention a risk to male fertility?

While the drug is explicitly restricted for use in women of childbearing potential, official documents have also noted risks to male reproductive health.

Studies indicate that the muscle relaxant component has been associated with impaired spermatogenesis (the development of sperm) and reproductive disorders in preclinical and post-marketing reports.

Q: Is the drowsiness effect caused by the muscle relaxant component or the painkiller?

Regulatory documents clarify that the drowsiness effect is primarily linked to the muscle relaxant component, Thiocolchicoside.

This is due to its known action on the central nervous system, which can cause sedative effects.

Q: Can taking Zerodol-TH for a long period increase the risk of kidney problems?

Yes, the NSAID component of the medicine carries a documented risk of kidney damage, medically known as nephrotoxicity.

This risk is specifically increased with prolonged use. For this reason, regulatory guidelines strictly designate treatment for short-term use only.

Q: Why is there a warning about fluid retention with Zerodol-TH?

The NSAID component (Aceclofenac) belongs to a class of medicines that can cause fluid retention and edema (swelling).

This is an important official warning, particularly relevant for individuals who have pre-existing conditions like heart failure or uncontrolled high blood pressure.

Q: What is the risk level of getting a rash or skin reaction from this drug?

Mild skin reactions, such as itching or a rash, are documented as less common side effects.

However, severe and potentially life-threatening skin reactions are also documented as rare adverse events and have been documented as requiring immediate medical attention.

Q: Are there specific blood pressure medications that interact negatively with Zerodol-TH?

Yes, the NSAID component of the medicine is known to interact with several classes of blood pressure medications.

This includes diuretics (water pills), ACE inhibitors, and Angiotensin II Receptor Antagonists. This interaction may reduce the blood pressure-lowering effect of these medicines.

Q: Why is Zerodol-TH not recommended for use in children?

According to official regulatory monographs, Zerodol-TH is not recommended or is strictly contraindicated for children and adolescents under 16 or 18 years of age, depending on the region.

This restriction is primarily because the safety and overall effectiveness of the combination medication have not been officially established in these younger age groups.

Q: What specific kidney conditions make Zerodol-TH use risky?

The medicine is strictly contraindicated for patients who have severe kidney impairment or severe renal failure.

Individuals with mild to moderate kidney disease are not absolutely restricted, and official information notes that cautious use and close medical supervision are indicated due to the risks associated with the NSAID component.

Q: Does Zerodol-TH interact with common antidepressants?

Yes, official interaction documents note that the NSAID component (Aceclofenac) can interact with Selective Serotonin Reuptake Inhibitors (SSRIs), which are a common type of antidepressant.

This combination is stated to potentially increase the risk of gastrointestinal bleeding.

Q: Why is Zerodol-TH usually avoided if a person has had recent bypass surgery?

Official guidance indicates that the NSAID component (Aceclofenac) is generally contraindicated following Coronary Artery Bypass Graft (CABG) surgery.

This restriction is due to increased cardiovascular risks associated with the use of NSAIDs after such major heart procedures and in established ischaemic heart disease.

Q: How quickly does Zerodol-TH usually start to relieve pain?

While individual responses vary, pharmacokinetic studies indicate that the combined medication generally begins to show its initial effects in pain relief within 30 minutes to one hour after ingestion.

This rapid action is due to the absorption characteristics of the active ingredients.

Q: What are the official recommendations about driving or operating machinery while on this medication?

Official prescribing information advises caution regarding complex tasks. Due to the potential for side effects such as dizziness, drowsiness, or vision problems, patients are advised to avoid driving or operating heavy machinery.

For this reason, it is advised that patients avoid such tasks until they are certain the medication does not impair their concentration or reaction time.

Q: Is Zerodol-TH considered an addictive medication?

The regulatory documentation and warnings for Zerodol-TH do not classify it as a narcotic or controlled substance.

The medicine is not considered habit-forming or addictive when it is used as directed for the short-term duration authorized by health authorities.

Q: Why do some formulations of Zerodol-TH have 'OD' in the name (e.g., Zerodol-TH OD)?

The letters 'OD' in a drug name typically refer to an 'Once Daily' dosing schedule.

These specific formulations are designed to be taken one time per day, which contrasts with other formulations prescribed for twice-daily use.

How should Zerodol-TH be stored and disposed of?

How to Store and Dispose of Zerodol-TH (Aceclofenac and Thiocolchicoside)

Official Storage Requirements

Zerodol-TH must be stored under specific, labeled conditions to maintain the stability of the active ingredients. The medicine must be stored below 30 C and requires mandatory protection from both light and moisture. To preserve its integrity, the tablets must be kept in the original container or pack, tightly closed. A critical safety rule requires that the medicine is kept out of the sight and reach of children.

Official Disposal Rules

Disposal of any unused or expired Zerodol-TH must be done according to official guidance to prevent environmental contamination. Regulatory instructions specify that the product must not be flushed down the toilet or disposed of into the drain. Any unused product must be disposed of in accordance with local requirements for pharmaceutical waste.

Zerodol-TH